Velocity Fund launches InClinica from acquired CRO IndiPharm

handshake

Pittsburgh’s Velocity Fund Partners has picked up CRO IndiPharm for an undisclosed amount, renaming the Philadelphia firm InClinica.

InClinica, as it is now called, boasts a specialty in early and midstage trials from Pennsylvania, and it also has locations in the U.K., Israel, Malaysia and Singapore. Velocity is looking to cash in on this global reach, positioning the CRO for growth down the road, according to a release.

With the acquisition, IndiPharm founder and president Edward Brennan will serve as InClinica’s chief medical officer, and Michael Fare will be chief operating officer and chief technical officer.

Webinar

How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

Bloomberg writes in an overview that one of Indipharm’s strategies is to provide Western biopharmas “a gateway for conducting clinical trials in India.” Currently, the company is managing a global Phase III clinical trial for lung cancer.

“InClinica’s existing global footprint and experience in early drug and device development and clinical trials, combined with Velocity’s unique experience and contacts in both healthcare and life sciences, will enable InClinica to provide companies with significant value in all clinical phases,” said Velocity Managing Partner Ken Melani.

“Many drugs fail to advance during clinical research for reasons unrelated to efficacy or safety,” Fare said. “An experienced clinical CRO can anticipate challenges and plan ahead, ensuring a smoother progression through clinical development.”

- here's the release

Related Article:
WCCT Global and cancer CRO Medelis to combine under merger deal

Read more on

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

PPD, which is going public (again) after years of being private, is ramping up its clinical research units (CRUs).

U.S.-China biotech Brii Biosciences is pushing out into new territory with a new hire alongside a focus on a new R&D area.